Cerity Partners LLC Has $1.41 Million Holdings in HealthEquity, Inc. (NASDAQ:HQY)

Cerity Partners LLC grew its position in HealthEquity, Inc. (NASDAQ:HQY) by 15.1% in the third quarter, according to its most recent filing with the SEC. The fund owned 17,259 shares of the company’s stock after acquiring an additional 2,258 shares during the period. Cerity Partners LLC’s holdings in HealthEquity were worth $1,413,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the company. GSA Capital Partners LLP bought a new stake in HealthEquity during the third quarter worth $638,000. Vaughan Nelson Investment Management L.P. boosted its holdings in shares of HealthEquity by 36.7% in the third quarter. Vaughan Nelson Investment Management L.P. now owns 843,423 shares of the company’s stock worth $69,034,000 after acquiring an additional 226,563 shares during the period. Natixis Advisors LLC grew its position in shares of HealthEquity by 29.8% in the third quarter. Natixis Advisors LLC now owns 209,175 shares of the company’s stock valued at $17,122,000 after purchasing an additional 48,009 shares in the last quarter. Oppenheimer Asset Management Inc. increased its position in shares of HealthEquity by 29.4% during the second quarter. Oppenheimer Asset Management Inc. now owns 64,214 shares of the company’s stock valued at $5,535,000 after buying an additional 14,573 shares during the period. Finally, Diversify Wealth Management LLC bought a new stake in shares of HealthEquity during the second quarter valued at about $8,182,000. 99.55% of the stock is currently owned by institutional investors.

Insider Buying and Selling

In other news, Director Frank Corvino sold 1,247 shares of the firm’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $80.26, for a total value of $100,084.22. Following the sale, the director now owns 4,823 shares in the company, valued at approximately $387,093.98. This trade represents a 20.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of the stock in a transaction that occurred on Wednesday, October 9th. The stock was sold at an average price of $82.98, for a total value of $684,585.00. Following the completion of the transaction, the director now directly owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. The trade was a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 10,536 shares of company stock valued at $884,517 in the last quarter. Company insiders own 2.20% of the company’s stock.

HealthEquity Trading Down 0.3 %

Shares of HQY stock opened at $101.39 on Wednesday. The business’s 50 day moving average is $90.61 and its two-hundred day moving average is $83.02. HealthEquity, Inc. has a twelve month low of $62.10 and a twelve month high of $105.82. The company has a market capitalization of $8.85 billion, a P/E ratio of 84.49, a price-to-earnings-growth ratio of 1.59 and a beta of 0.55. The company has a current ratio of 4.10, a quick ratio of 4.10 and a debt-to-equity ratio of 0.51.

HealthEquity (NASDAQ:HQY) last posted its earnings results on Tuesday, September 3rd. The company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.50 by $0.16. The firm had revenue of $299.93 million for the quarter, compared to analyst estimates of $284.48 million. HealthEquity had a return on equity of 9.01% and a net margin of 9.61%. Equities analysts forecast that HealthEquity, Inc. will post 2.27 EPS for the current year.

Analyst Upgrades and Downgrades

HQY has been the topic of a number of recent analyst reports. Bank of America raised their target price on shares of HealthEquity from $100.00 to $120.00 and gave the company a “buy” rating in a research note on Wednesday, November 13th. JMP Securities restated a “market outperform” rating and issued a $105.00 target price on shares of HealthEquity in a research report on Wednesday, September 4th. The Goldman Sachs Group started coverage on shares of HealthEquity in a research note on Friday, November 15th. They set a “neutral” rating and a $108.00 price target on the stock. Barrington Research upped their price objective on shares of HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday. Finally, BTIG Research upped their price target on shares of HealthEquity from $110.00 to $130.00 and gave the company a “buy” rating in a research report on Thursday, November 14th. One equities research analyst has rated the stock with a hold rating and twelve have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $108.38.

About HealthEquity

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.